Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases

Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases

Abstract Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupilumab. We experienced two patients with immediate e...

Full description

Bibliographic Details
Main Authors: Makoto Ito, Masahiro Kamata, Hideaki Uchida, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Yayoi Tada
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Journal of Cutaneous Immunology and Allergy
Subjects:
atopic dermatitis
biologics
dupilumab
Janus kinase
upadacitinib
Online Access:https://doi.org/10.1002/cia2.12302

Similar Items

Similar Items